Figure 4. Kaplan-Meier analysis of 5-year relapse-free survival (RFS) and 5-year disease-specific survival (DSS) for B-cell lymphoma 2 (BCL2)-positive and BCL2-negative breast cancer patients. BCL2-positive luminal B, human epidermal growth factor receptor 2 (HER2) overexpression, and triple-negative breast cancer (TNBC) breast cancer patients have no longer 5-year RFS (A, C, E, and G) and 5-year DSS (B, D, F, and H) compared to patients with no BCL2 expression.
